Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau.
In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease.
Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies.
Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3.
The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company.
AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -0.16 Decreased by -220.00% | -0.19 Increased by +15.92% |
| Nov 1, 24 | 0.06 Increased by +133.33% | -0.23 Increased by +126.09% |
| Aug 6, 24 | -0.23 Decreased by -15.00% | 0.27 Decreased by -185.19% |
| May 13, 24 | -0.18 Increased by +14.29% | -0.14 Decreased by -28.57% |
| Mar 14, 24 | -0.05 Increased by +78.26% | -0.11 Increased by +54.55% |
| Nov 3, 23 | -0.18 Decreased by -12.50% | 0.03 Decreased by -700.00% |
| Aug 4, 23 | -0.20 Increased by +13.04% | -0.19 Decreased by -5.26% |
| Apr 28, 23 | -0.21 Increased by +8.70% | -0.23 Increased by +8.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 990.00 K Increased by +44.10% | -19.03 M Decreased by -6.53% | Decreased by -1.92 K% Increased by +26.07% |
| Dec 31, 24 | 1.14 M Decreased by -92.32% | -15.80 M Decreased by -232.99% | Decreased by -1.39 K% Decreased by -4.23 K% |
| Sep 30, 24 | 25.48 M Increased by +N/A% | 5.50 M Increased by +136.34% | Increased by +21.59% Decreased by N/A% |
| Jun 30, 24 | 687.00 K Increased by +N/A% | -22.76 M Decreased by -35.21% | Decreased by -3.31 K% Decreased by N/A% |
| Mar 31, 24 | 687.00 K Increased by +N/A% | -17.86 M Decreased by -1.99% | Decreased by -2.60 K% Decreased by N/A% |
| Dec 31, 23 | 14.80 M Increased by +1.48 M% | -4.74 M Increased by +74.70% | Decreased by -32.05% Increased by +100.00% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -15.14 M Decreased by -12.04% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -16.83 M Increased by +14.31% | Decreased by N/A% Decreased by N/A% |